|
1
|
Ronsin C, Muscatelli F, Mattei MG and
Breathnach R: A novel putative receptor protein tyrosine kinase of
the met family. Oncogene. 8:1195–1202. 1993.PubMed/NCBI
|
|
2
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gaudino G, Follenzi A, Naldini L, et al:
RON is a heterodimeric tyrosine kinase receptor activated by the
HGF homologue MSP. EMBO J. 13:3524–3532. 1994.PubMed/NCBI
|
|
4
|
Angeloni D, Danilkovitch-Miagkova A,
Ivanov SV, et al: Gene structure of the human receptor tyrosine
kinase RON and mutation analysis in lung cancer samples. Genes
Chromosomes Cancer. 29:147–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Follenzi A, Bakovic S, Gual P, Stella MC,
Longati P and Comoglio PM: Cross-talk between the proto-oncogenes
Met and Ron. Oncogene. 19:3041–3049. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang MH, Ronsin C, Gesnel MC, et al:
Identification of the ron gene product as the receptor for the
human macrophage stimulating protein. Science. 266:117–119. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Danilkovitch A and Leonard EJ: Kinases
involved in MSP/RON signaling. J Leukoc Biol. 65:345–348.
1999.PubMed/NCBI
|
|
8
|
Longati P, Bardelli A, Ponzetto C, Naldini
L and Comoglio PM: Tyrosines1234–1235 are critical for activation
of the tyrosine kinase encoded by the MET proto-oncogene (HGF
receptor). Oncogene. 9:49–57. 1994.PubMed/NCBI
|
|
9
|
Iwama A, Yamaguchi N and Suda T: STK/RON
receptor tyrosine kinase mediates both apoptotic and growth signals
via the multifunctional docking site conserved among the HGF
receptor family. EMBO J. 15:5866–5875. 1996.PubMed/NCBI
|
|
10
|
Danilkovitch-Miagkova A: Oncogenic
signaling pathways activated by RON receptor tyrosine kinase. Curr
Cancer Drug Targets. 3:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Q, Seol DW, Carr B and Zarnegar R:
Co-expression and regulation of Met and Ron proto-oncogenes in
human hepatocellular carcinoma tissues and cell lines. Hepatology.
26:59–66. 1997.PubMed/NCBI
|
|
12
|
Maggiora P, Marchio S, Stella MC, et al:
Overexpression of the RON gene in human breast carcinoma.
Oncogene. 16:2927–2933. 1998.
|
|
13
|
Wang MH, Yao HP and Zhou YQ: Oncogenesis
of RON receptor tyrosine kinase: a molecular target for malignant
epithelial cancers. Acta Pharmacol Sin. 27:641–650. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Y, Yao HP and Wang MH: Multiple
variants of the RON receptor tyrosine kinase: biochemical
properties, tumorigenic activities, and potential drug targets.
Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Collesi C, Santoro MM, Gaudino G and
Comoglio PM: A splicing variant of the RON transcript induces
constitutive tyrosine kinase activity and an invasive phenotype.
Mol Cell Biol. 16:5518–5526. 1996.PubMed/NCBI
|
|
16
|
Ghigna C, Giordano S, Shen H, et al: Cell
motility is controlled by SF2/ASF through alternative splicing of
the Ron protooncogene. Mol Cell. 20:881–890. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wahl MC, Will CL and Luhrmann R: The
spliceosome: design principles of a dynamic RNP machine. Cell.
136:701–718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moore MJ and Proudfoot NJ: Pre-mRNA
processing reaches back to transcription and ahead to translation.
Cell. 136:688–700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han J, Xiong J, Wang D and Fu XD: Pre-mRNA
splicing: where and when in the nucleus. Trends Cell Biol.
21:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Black DL: Mechanisms of alternative
pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blencowe BJ: Alternative splicing: new
insights from global analyses. Cell. 126:37–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keren H, Lev-Maor G and Ast G: Alternative
splicing and evolution: diversification, exon definition and
function. Nat Rev Genet. 11:345–355. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grabowski PJ and Black DL: Alternative RNA
splicing in the nervous system. Prog Neurobiol. 65:289–308. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
David CJ and Manley JL: Alternative
pre-mRNA splicing regulation in cancer: pathways and programs
unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee J, Zhou J, Zheng X, et al:
Identification of a novel cis-element that regulates
alternative splicing of Bcl-x pre-mRNA. Biochem Biophys Res Commun.
420:467–472. 2012.
|
|
26
|
Cho S, Moon H, Yang X, et al: Validation
of trans-acting elements that promote exon 7 skipping of SMN2 in
SMN2-GFP stable cell line. Biochem Biophys Res Commun. 423:531–535.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kan JL and Green MR: Pre-mRNA splicing of
IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer
and inhibitor. Genes Dev. 13:462–471. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen H, Kan JL, Ghigna C, Biamonti G and
Green MR: A single polypyrimidine tract binding protein (PTB)
binding site mediates splicing inhibition at mouse IgM exons M1 and
M2. RNA. 10:787–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
